Phio制药公司已与H.C. Wainwright达成一项市场发行协议,并于2026年4月8日向美国证券交易委员会提交了相关文件。该协议的签署标志着公司融资策略的重要进展,为未来业务拓展提供了资金支持。
Phio制药公司已与H.C. Wainwright达成一项市场发行协议,并于2026年4月8日向美国证券交易委员会提交了相关文件。该协议的签署标志着公司融资策略的重要进展,为未来业务拓展提供了资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.